Program
pirfenidone
Also written as “Pirfenidone”, “Pirfenidone Modified-Release Tablets” and “Deupirfenidone”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Lung Injury · Lung Diseases, Interstitial · Pulmonary Fibrosis · COVID-19, led by 6 companies.
Drug pagePirfenidone: every studyMany companies study it; this page follows only the 29 they lead. All 102 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 120 open or running | phase 4since Nov 4, 2015 | Mar 24, 2004 | none ahead |
| GNI Groupits history only | 72 open or running | phase 3since Feb 26, 2019 | Nov 18, 2014 | Dec 30, 2026phase 3 · NCT07388680 |
| PureTechits history only | 52 open or running | phase 3since Dec 8, 2025 | Jan 21, 2020 | Nov 2029phase 3 · NCT07284602 |
| Overseas Pharmaceuticalsits history only | 30 open or running | phase 1since Aug 22, 2024 | Aug 22, 2024 | none ahead |
| beijing-kawin-technology-share-holding-co-ltdits history only | 10 open or running | phase 2since Dec 30, 2011 | Dec 30, 2011 | none ahead |
| grupo-medifarma-s-a-de-c-vits history only | 10 open or running | phase 3since Jul 6, 2015 | Jul 6, 2015 | none ahead |
Also a collaborator on its studies: Clinipace Worldwide, Novotech (Australia) Pty, Shanghai Genomics and GNI-EPS Pharmaceuticals, Inc. (GNI Group).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2004First study: phase 2 study in Idiopathic Pulmonary FibrosisFirst studyNCT00080223 · 83 enrolled · United States
- Feb 6, 20062 phase 3 studies in Idiopathic Pulmonary FibrosisNCT00287729, NCT00287716
- Apr 17, 2008Phase 3 study in Idiopathic Pulmonary FibrosisNCT00662038 · 1,058 enrolled · United States
- Jun 2, 2011Phase 3 study in Idiopathic Pulmonary FibrosisNCT01366209 · 555 enrolled · United States
- Jun 5, 2013Phase 2 study in Idiopathic Pulmonary FibrosisNCT01872689 · 505 enrolled · United States, Australia, Belgium and more
- Aug 23, 2013Phase 2 study in Scleroderma, SystemicNCT01933334 · 63 enrolled · United States, Canada, Italy
- Aug 14, 2015Phase 1 study in Healthy VolunteerNCT02525484 · 44 enrolled · United States
- Nov 4, 2015Phase 4 study in Idiopathic Pulmonary FibrosisNCT02598193 · 89 enrolled · United States, Canada, Denmark and more
- Jan 5, 2016Phase 1 study in Idiopathic Pulmonary FibrosisNCT02648048 · 21 enrolled · United States, Germany
- Mar 31, 2017Phase 2 study in Lung Diseases, InterstitialNCT03099187 · 253 enrolled · Australia, Belgium, Canada and more
- Jun 26, 2017Phase 3 study in Idiopathic Pulmonary FibrosisNCT03208933 · 60 enrolled · Russian Federation
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03208933Idiopathic Pulmonary Fibrosis · Russian Federation | 3 | Completed | Nov 13, 2019 | 60 |
| NCT03099187Lung Diseases, Interstitial · Australia, Belgium, Canada and more | 2 | Completed | Nov 21, 2018 | 253 |
| NCT02648048Idiopathic Pulmonary Fibrosis · United States, Germany | 1 | Completed | Nov 30, 2016 | 21 |
| NCT02598193Idiopathic Pulmonary Fibrosis · United States, Canada, Denmark and more | 4 | Completed | May 16, 2017 | 89 |
| NCT02525484Healthy Volunteer · United States | 1 | Completed | Aug 2015 | 44 |
| NCT01933334Scleroderma, Systemic · United States, Canada, Italy | 2 | Completed | Sep 2014 | 63 |
| NCT01872689Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more | 2 | Completed | Jul 28, 2017 | 505 |
| NCT01366209Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Feb 2014 | 555 |
| NCT00662038Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Feb 2016 | 1,058 |
| NCT00287729Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Nov 2008 | 344 |
| NCT00287716Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Nov 10, 2008 | 435 |
| NCT00080223Idiopathic Pulmonary Fibrosis · United States | 2 | Completed | Apr 30, 2015 | 83 |
How it is read
Names in the registry
- “Pirfenidone”, 26 entries
- “Pirfenidone Modified-Release Tablets”, 4 entries
- “Deupirfenidone”, 3 entries
- “pirfenidone capsule”, 2 entries
- “pirfenidone”, 2 entries
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 21 studies
- Lung Injury, 2 studies
- Lung Diseases, Interstitial, 2 studies
- Pulmonary Fibrosis, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.